CD276 and cancer: Recent studies showed that targeting B7-H3 by chimeric antigen receptor T cells exhibited superior and safe antitumor effects 26, 27, indicating that B7-H3 is crucial for modulating the antitumor immune response and that targeting B7-H3 is a potential immunotherapeutic strategy for cancer treatment.